Login / Signup

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

Richard E ClarkAmmar A BasabrainGemma M AustinAlison K HolcroftSandra LoaizaJane F ApperleyChristopher LawLaura ScottAlexandra D ParryLaura Jayne BonnettClaire M Lucas
Published in: Cancers (2021)
These data confirm that high diagnostic CIP2A levels correlate with subsequent disease progression and treatment failure. CIP2A is a simple diagnostic biomarker that may be useful in planning treatment strategies.
Keyphrases
  • bone marrow
  • dendritic cells
  • electronic health record
  • big data
  • combination therapy
  • deep learning
  • artificial intelligence